Targeted Therapies For Atopic Dermatitis: On the Cusp of a Golden Era? - POCN
:Home>>Targeted Therapies For Atopic Dermatitis: On the Cusp of a Golden Era?

Targeted Therapies For Atopic Dermatitis: On the Cusp of a Golden Era?

Immunology | February 8, 2022


1.0 AMA PRA Category 1 Credit™
1.0 Medical Knowledge ABIM MOC Point

Click to Register/login And Complete Your Free Webcourse

Launch Date:

February 8, 2022

Expiration Date:

February 8, 2023

primary audience:

Allergists and dermatologists who manage patients with moderate to severe AD

Relevant Terms:

Anti-interleukin monoclonal antibodies, Assessment tools, Atopic dermatitis, Th2 cytokines

course information

Approximately one-third of patients with atopic dermatitis (AD) have severe disease that requires systemic treatment directed at controlling immune responses. In recent years, novel therapies targeting the underlying pathophysiology of AD have been approved with many more emerging, but many clinicians lack familiarity with these new and emerging agents as well as related mechanisms of action and safety and efficacy profiles. Furthermore, clinicians often underestimate AD disease severity and the impact on patient’s quality of life (QoL), leading to undertreatment.

“Targeted Therapies For Atopic Dermatitis: On the Cusp of a Golden Era?” aims to provide allergists and dermatologists with up-to-date information on management of moderate to severe AD, including the health burden of uncontrolled disease, identification of patients with more severe disease who require treatment escalation, evidence-based use of newer targeted therapies, and how emerging therapies may impact AD management in the near term.

Welcome and IntroductionsThe Role of Inflammatory Processes and Related Physiologic Pathways in AD Pathology
Assessing and Managing Moderate-to-Severe AD
Expanding Treatment Landscape for AD
Q&A Session and Activity Roundup


Peter Lio, MD
Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director, Chicago Integrative Eczema Center
Chicago, IL
Peter Lio, MD is a Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University. He received his medical degree from Harvard Medical School and his Dermatology training at Harvard. While at Harvard, he received formal training in acupuncture. Dr. Lio is the founding director of the Chicago Integrative Eczema Center and a founding faculty member of the Integrative Dermatology Certificate Program with over 200 publications and 3 textbooks.
Jonathan M. Spergel, MD, PhD
Professor of Pediatrics
Chief, Allergy Section
Stuart E. Starr Chair of Pediatrics
Director of Center for Pediatric Eosinophilic Disease
The Children’s Hospital of Philadelphia
Perelman School of Medicine at Univ. of Pennsylvania
Philadelphia, PA
Jonathan M. Spergel, MD, PhD is a Professor of Pediatrics at the University of Pennsylvania School of Medicine and Chief of the Allergy Section at Children’s Hospital of Philadelphia. He is also holder of the Stuart Starr Chair of Pediatrics and Director of Center for Eosinophilic Diseases. He received his medical and graduate education at the Mount Sinai School of Medicine and completed his pediatric residency at Yale-New Haven Hospital. His clinical and post-graduate research training in Allergy and Immunology were completed at Children’s Hospital, Harvard Medical School, Boston, MA. Dr. Spergel is Board Certified in Pediatrics and Allergy and Immunology. He is a fellow in American Academy of Allergy Asthma and Immunology (AAAAI), American College of Allergy, Asthma and Immunology, American Assoc of Pediatrics, Philadelphia College of Physicians and others. He has severed on national and international committees on food allergy, atopic dermatitis and eosinophilic esophagitis. Dr. Spergel is the principal investigator for multiple studies in the fields of atopic dermatitis, eosinophilic esophagitis and food allergies. He has published over 300 articles in the field. He has spoken national and international in the field of eosinophilic esophagitis, food allergy and atopic dermatitis.
His current research focuses on both clinical (desensitization and tolerance) in Eosinophilic Esophagitis and Food Allergy and translational research (molecular mechanisms in Eosinophilic Esophagitis and food allergy.

This activity is intended for allergists and dermatologists who manage patients with moderate to severe AD.

At the conclusion of this education, participants should be able to:

  • Describe the role of type 2 inflammatory processes in the pathophysiology of atopic dermatitis
  • Utilize evidence-based disease assessment tools to identify patients with moderate to severe atopic dermatitis
  • Implement shared decision-making into routine practice to incorporate patient goals and needs into multidisciplinary atopic dermatitis action plans
  • Evaluate the safety and efficacy of current and emerging targeted therapies for moderate to severe atopic dermatitis

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for clinicians.

The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Clinicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME/MOC/MIPS credit or the evaluation, please email

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory,
“Targeted Therapies for Atopic Dermatitis: On the Cusp of a Golden Era?” has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

ABMS Lifelong Learning CME Activity
Allergy and Immunology
Family Medicine

Dermatologists certified by the American Board of Dermatology (ABD) must earn a minimum of 25 hours of AMA PRA Category 1 CreditsTM annually. Half of these credits must be Dermatology practice-specific CME credits from accredited organizations in order to fulfill the lifelong learning component of MOC. Participation in this activity will support board certified dermatologists in contributing towards this MOC requirement set forth by the ABD.

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

In order to fulfill requirements for MIPS improvement activity, participants will need to fill out 2 brief follow-up surveys at 30- and 90-days post-activity.

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by PCME.

Faculty, Authors, and Content Developers
The faculty, authors and content developers reported the following relevant financial relationships with ineligible companies:

Peter Lio, MD: Grant/Research Support: AbbVie, AOBiome, Regeneron/Sanofi Genzyme; Honoraria: AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN Pharmaceuticals, Bodewell, Boston Skin Science LLC, Burt’s Bees, Castle Biosciences, Dermavant, Eli Lilly, Exeltis, Galderma, IntraDerm, Johnson & Johnson, Kimberly-Clark, LEO Pharmaceuticals, L’Oreal, Menlo Therapeutics, Micreos, MYOR, Pierre-Fabre, Pfizer, Regeneron/Sanofi Genzyme, Theraplex, Unilever, Verrica, YobeeCare; Speaker’s Bureau: Galderma, Eli Lilly, LEO Pharmaceuticals, L’Oreal, Pfizer, Regeneron/Sanofi Genzyme; Stock Shareholder (Stock Options): Altus Labs, Boston Skin Science LLC, Micreos, YobeeCare; Patent Pending: Theraplex AIM

Jonathan M. Spergel, MD, PhD: Consulting Fee: Novartis, Regeneron, Sanofi, Takeda; Contracted Research: Novartis, Regeneron, Sanofi, Takeda

Planners and Managers
The planners and managers reported the following relevant financial relationships with ineligible companies:

Chad Williamson, MS, MBA, CMPP: has no relevant relationships

Content Reviewers
The content reviewers reported the following relevant financial relationships with ineligible companies:

Katie Propst, PhD: has no relevant relationships

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/MOC/MIPS activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.

Click here for the MIPS Information

Jointly provided by the Potomac Center for Medical Education and Rockpointe

This program is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Go to Top